The Science and Quality Fellow Program advances the fields of guidelines and quality and data. It also helps residents and fellows develop insight into how the AUA develops and promotes the advancement of evidence-based science.
- Open to all AUA residents in their research year, fellows, and first year post-graduates
- Applicants will demonstrate a strong interest or aptitude for science and quality issues
- If the applicant is currently a resident, the Fellow's Resident Director must sign-off on and verify that the Fellow will be available for the travel and time allotted for the program
The program runs for 12 months beginning each May. To be considered, applications must be submitted by February 1 for the upcoming May program cycle.
The 2022 application cycle is closed.
2022-2023 Science and Quality Fellow
David F. Friedlander, MD, MPH
David F. Friedlander, MD, MPH, is an assistant professor of urology at the University of North Carolina School of Medicine. After graduating from Bowdoin College, he spent a year working in the California state capitol as a research fellow in the office of the vice-chair of the health committee. Dr. Friedlander received his medical degree from Vanderbilt University in Nashville, Tenn., during which time he also completed an MPH at the Harvard TH Chan School of Public Health. He subsequently completed his residency at Brigham and Women’s Hospital in Boston, Mass., where he stayed on for an NIH-funded research fellowship. He then completed a clinical fellowship in endourology and minimally invasive surgery at the University of California-San Diego. His research interests include understanding how healthcare policy effects surgical outcomes and costs, as well as understanding both clinical and social factors that influence the quality of healthcare delivery. He was recently awarded a two-year AUA Research Scholars Grant to investigate the aforementioned topics as they pertain to the treatment of urolithiasis. His clinical interests include the surgical and medical management of urinary stones and benign prostatic hyperplasia.